Dr. Oliver Kepp graduated from Humboldt University Berlin and obtained a PhD degree in Molecular Biology for his work on "Host cell apoptosis" conducted at the Max Planck Institute for Infection Biology. Following this he was a Max Planck postdoctoral research fellow and in 2007 joined the INSERM team headed by Prof. Guido Kroemer at the Gustave Roussy Cancer Center (GRCC) as an EMBO postdoc fellow. He is now a research director at INSERM and the director of the BioCell automation platform at GRCC. In his work, he together with his team investigate several aspects of tumor immunogenicity, focusing on systematic cell biology approaches. Oliver has published about 350 scientific articles and has a Hirsch factor of 109 (scholar.google.com). He is a member of several editorial boards, a co-founder of Samsara Therapeutics, and was appointed associate director of the European academy of tumor immunology in 2019. Oliver has received the prestigious Clarivate Highly Cited Researcher Award six years in a row, since 2018, and has recently been ranked among the top biology and biochemistry scientists in the world (www.research.com).